<div id="readability-page-1"><div><p>Brokers | Investment Ratings | TPs | Key Views</p><p>Citi | Buy | HKD9 -&gt; 8 | FY2027 profit guidance is conservative, mainly due to proactive reinvestment of operating profit into innovative drugs and AI applications. The company is transforming from an e-commerce platform into a full-stack pharmaceutical operator, with medical AI as a future growth engine. Current online sales of GLP-1 weight-loss drugs are not affected by regulatory adjustments. Despite the TP cut, it remains a top pick.</p><p>BofA Securities | Buy | HKD6 | Last fiscal year results were in line with company guidance, but growth slowed in 2H due to weak performance in the medical devices category. The declaration of final and special dividends totaling RMB3.14 billion (implying a dividend yield of about 5%) surprised the market. Positive on enhanced shareholder returns and the launch of the doctor-oriented AI model &#34;Hydrogen Ion&#34;.</p><p>CLSA | Outperform | HKD5.3 -&gt; 4.7 | 2H revenue slightly missed expectations, while profit met forecasts. Prescription drugs, OTC and nutritional products maintained healthy growth, but 2H third-party platform revenue declined due to reduced medical device subsidies and VAT impact on adult products. Future profit is expected to be weighed down by investments in the innovative drug supply chain and medical AI.</p><p>HSBC Research | Hold | HKD5.5 -&gt; 4.5 | 2H revenue growth slowed to 8%, below the broker and market expectation of 14%. The company has entered an investment phase, focusing on strengthening end-to-end services such as cold-chain warehousing. The medical AI app &#34;Hydrogen Ion&#34; targets 2 million monthly active doctors within three years. Although the dividend yield of 5% is attractive, earnings forecasts were cut due to investment impact.</p><p>UBS | Sell | HKD4.1 -&gt; 3.6 | Revenue for the last fiscal year missed target, and FY2027 adjusted net profit guidance was below buy-side expectations due to increased investment. While the strategic focus on pharmaceuticals supports revenue, a higher proportion of first-party drug sales will compress gross margin. The company faces competitive advantages from JD Health in user mindshare and supply chain. FY2027-29 earnings forecasts were cut by 12-14%.</p><p>(da/a)</p></div></div>

00241

159929

512010

510660

<p>Brokers have provided updated ratings and target prices for ALI HEALTH. Citi maintains a 'Buy' rating with a target price of HKD8, citing conservative profit guidance due to reinvestments. BofA Securities also rates it 'Buy' at HKD6, highlighting unexpected dividends. CLSA's 'Outperform' rating drops to HKD4.7, while HSBC Research holds at HKD4.5, noting slowed revenue growth. UBS rates it 'Sell' with a target of HKD3.6, citing missed revenue targets and reduced profit forecasts.</p>

AASTOCKS News

ALI HEALTH

China Universal 800 Health Care ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Citigroup

Bank of America

TE HEALTHCARE

HSBC HOLDINGS

HSBC

UBS Group AG

JD HEALTH

CITIGROUP INC 6.250 NON CUM SER II PFD WI

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

HSBC 5xShortSG241213

HSBC Holdings Plc

JD HEALTH-R

Summary of Latest Ratings, TP, Views on ALI HEALTH from Brokers